Juvenile Idiopathic Arthritis Clinical Trial
— RUMAJIOfficial title:
Representation and Medication Use in Juvenile Idiopathic Arthritis - RUMAJI
| Verified date | March 2019 |
| Source | University Hospital, Montpellier |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
According to the International League of Associations for Rheumatology classification, Juvenile Idiopathic Arthritis (JIA) comprises a heterogeneous group of arthritis of unknown cause and with onset before 16 years of age, characterized by joint inflammation lasting for 6 or more weeks. Few studies exist regarding the care experience of children affected by this rheumatic condition. On the other hand, methotrexate and biologics constitute the primary treatment for children with JIA. As with adults undergoing the same treatment, adherence is critical. Difficulties for children to take the drugs have been reported. Notwithstanding, if adherence promotion in pediatric chronic conditions has been the subject of recommendations with regard to care management, the investigators lack information to understand the grounds for adherence specifically in JIA. In order to understand and decipher the parent-child adherence mechanisms and practices, the RUMAJI study will be conducted. Indeed, improving the relational approach between children and their caregivers as well as unrestricted drug adherence involves researching and understanding how appropriation of the disease and treatment could be achieved.
| Status | Completed |
| Enrollment | 36 |
| Est. completion date | December 1, 2017 |
| Est. primary completion date | October 1, 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 1 Year to 17 Years |
| Eligibility |
Inclusion criteria: - all JIA forms - all treatment type (NSAIDs, MTX, bDMARDs) Exclusion criteria: - none |
| Country | Name | City | State |
|---|---|---|---|
| France | Uhmontpellier | Montpellier |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Montpellier | NORDIC pharma (funding), Research department, unknowns, Strategic & innovation consulting, Paris (anthropologists) |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Interview with parents | Interview with parents to learn about role of parents in the management of juvenile idiopathic arthritis in their children | 1 day | |
| Secondary | Interview with children | Interview with children to learn about role of children in the management of their juvenile idiopathic arthritis | 1 day | |
| Secondary | Interview with physicians | Interview with physicians to learn about role of physicians in the management of juvenile idiopathic arthritis | 1 day |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02776735 -
An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)
|
Phase 2 | |
| Active, not recruiting |
NCT03092427 -
Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA)
|
N/A | |
| Not yet recruiting |
NCT05545098 -
MSUS Versus Serum Survivin and Lubricin Levels in Evaluation of Disease Activity in JIA
|
||
| Not yet recruiting |
NCT03833609 -
Yoga and Aerobic Dance for Pain Management in Juvenile Idiopathic Arthritis
|
N/A | |
| Completed |
NCT02524340 -
Patient Centered Adaptive Treatment Strategies Using Bayesian Causal Inference
|
||
| Recruiting |
NCT01434082 -
Sleep Patterns in Children With and Without Juvenile Idiopathic Arthritis
|
N/A | |
| Completed |
NCT04671524 -
The Effect of Improvement in Function on Foot Pressure, Balance and Gait in Children With Upper Extremity Affected
|
N/A | |
| Recruiting |
NCT04167488 -
Assessment of Physical Activity Among Juvenile Idiopathic Arthritis Children Performed With Actigraphy
|
N/A | |
| Recruiting |
NCT04205500 -
Treatment With Specific Carbohydrate Diet in Children With Juvenile Idiopathic Arthritis
|
N/A | |
| Terminated |
NCT01694264 -
Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα
|
Phase 3 | |
| Completed |
NCT02824978 -
Therapeutic Alliance is it Associated With Better Compliance Amongst Children With Juvenile Idiopathic Arthritis ?
|
||
| Active, not recruiting |
NCT03841357 -
Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
|
Phase 3 | |
| Completed |
NCT03833271 -
The Efficacy of Influenza Vaccine Program in Children With Juvenile Idiopathic Arthritis. A Single Centre Results From Hungary
|
Early Phase 1 | |
| Completed |
NCT01455701 -
A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)
|
Phase 1 | |
| Completed |
NCT05031104 -
Low-energy Laser Applications in Patients With Juvenile Idiopathic Arthritis
|
N/A | |
| Not yet recruiting |
NCT01436019 -
Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis
|
N/A | |
| Recruiting |
NCT05609630 -
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
|
Phase 3 | |
| Recruiting |
NCT05696340 -
Access to Pediatric Rheumatology Centers for JIA Patients: Factors Associated With Time to Access Pediatric Rheumatology Centers
|
||
| Recruiting |
NCT05545839 -
Transition to Adulthood Through Coaching and Empowerment in Rheumatology
|
N/A | |
| Completed |
NCT05436301 -
Turkish Validity and Reliability of Pain Catastrophizing Scale-Child (PCS-C)
|